M
Montara Therapeutics
Precision-medicine neuroscience biotech startup striving to make innovative therapies that improve outcomes for people with CNS diseases
About Montara Therapeutics
Montara Therapeutics is a biopharmaceutical company focused on developing safer and more effective therapies for central nervous system (CNS) diseases. The company's approach is centered around its proprietary BrainOnly platform, which is designed to deliver drugs exclusively to the brain, thereby minimizing the peripheral side effects that are often a major limitation of current neuroscience treatments.
The BrainOnly platform utilizes a two-drug combination strategy. The first drug is the active therapeutic agent, which is modified to be inactive until it reaches the brain. The second drug is an activating enzyme that is delivered only to the brain. This enzyme then activates the therapeutic drug at the target site, ensuring that its effects are localized to the central nervous system.
Montara's initial focus is on developing treatments for neurological and psychiatric disorders, as well as brain cancers. The company's business model is based on advancing its drug candidates through preclinical and clinical development, with the ultimate goal of partnering with larger pharmaceutical companies for commercialization. By addressing the challenge of peripheral side effects, Montara aims to unlock the full potential of promising neuroscience drug candidates that have previously failed in development due to toxicity issues.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2023
- Headquarters
- San Francisco, United States
- Employees
- 25
- Open positions
- None listed
- Dealroom signal
- 88.3/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Precision Medicine, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GRANT✓Other financing | Jun 2026 | $1M | — | Michael J. Fox Foundation for Parkinson's Research | ↗ |
| SEED✓Equity / VC | Mar 2025 | $20M | $80M | SV Health Investors · Two Bear Capital · BEVC · Dolby Family Ventures | ↗ |
Growth signals
Latest recorded traffic for Montara Therapeutics is 2.2K monthly website visits, down 4.3% over the last three months. Montara Therapeutics's team grew 13.6% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed7 investors entered at this stage
Dementia Discovery Fund
Two Bear Capital
Dolby Family Ventures
KdT Ventures
SV Health Investors
BEVC
Michael J. Fox Foundation for Parkinson's Research
Other known investors1 additional known investor
University of California, San Francisco
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Montara Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Montara Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.